Celtic Pharma has announced the acquisition of a stake in IDEA - a
biopharma company, which is developing targeted therapeutics based
on novel, Transfersome carriers that can increase drug potency and
diminish harmful side effects.
US officials attempted to restore the reputation of the
pharmaceutical industry by announcing plans to introduce an
independent board, which aims to monitor the safety of drugs on the
market.
A new report suggests that recent safety concerns over certain
blockbuster drugs, notably Merck's Vioxx (rofecoxib) and Pfizer's
Celebrex (celecoxib), has placed the COX-2 inhibitor drug class
under intense scrutiny and...
The safety of cox-2 inhibitors was plunged into further uncertainty
after Pfizer released details of trials that found an increased
risk of heart problems with patients taking its painkiller
Celebrex. The drug is in the same class...
A new study suggests that there are important differences between
Merck & Co's Vioxx (rofecoxib) and other COX-2 inhibitors and
that this may account for variations in cardiovascular safety
within this drug class, writes...
Drug company Merck, has presented data this week showing its latest
arthrirtis drug, Arcoxia, a treatment in the same class as its
recently withdrawn Vioxx, displays no significant difference in the
number of serious side effects...